During the past decade, Kliniken Essen-Mitte conducted 77 clinical trials. In the 10-year time frame, 77 clinical trials started and 15 clinical trials were completed, i.e. on average, 19.5% percent of trials that started reached the finish line to date. In the past 5 years, 34 clinical trials started and 14 clinical trials were completed. i.e. 41.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kliniken Essen-Mitte" #1 sponsor was "Celgene" with 9 trials, followed by "European Organisation for Research and Treatment of Cancer - EORTC" with 8 trials sponsored, "Hoffmann-La Roche" with 6 trials sponsored, "University of Ulm" with 5 trials sponsored and "AGO Research GmbH" with 5 trials sponsored. Other sponsors include 73 different institutions and companies that sponsored additional 56 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kliniken Essen-Mitte" #1 collaborator was "Hoffmann-La Roche" with 6 trials as a collaborator, "Pfizer" with 5 trials as a collaborator, "German Breast Group" with 4 trials as a collaborator, "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 3 trials as a collaborator and "Merck Sharp & Dohme LLC" with 3 trials as a collaborator. Other collaborators include 96 different institutions and companies that were collaborators in the rest 88 trials.

According to Clinical.Site data, the most researched conditions in "Kliniken Essen-Mitte" are "Ovarian Cancer" (12 trials), "Breast Cancer" (9 trials), "Colorectal Cancer" (7 trials), "Acute Myeloid Leukemia" (5 trials) and "Crohn Disease" (5 trials). Many other conditions were trialed in "Kliniken Essen-Mitte" in a lesser frequency.

Most popular intervention types in "Kliniken Essen-Mitte" are "Drug" (82 trials), "Procedure" (16 trials), "Other" (13 trials), "Biological" (6 trials) and "Device" (6 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (12 trials), "Placebo" (12 trials), "Gemcitabine" (8 trials), "Paclitaxel" (7 trials) and "Atezolizumab" (6 trials). Other intervention names were less common.

The vast majority of trials in "Kliniken Essen-Mitte" are 76 trials for "All" genders, 31 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Kliniken Essen-Mitte". 1 are not yet recruiting, 27 are recruiting, 22 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 44 completed trials in Kliniken Essen-Mitte, 1 suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Kliniken Essen-Mitte, 4 "Phase 1" clinical trials were conducted, 30 "Phase 2" clinical trials and 51 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 16 trials that are defined as “Not Applicable".

Kliniken Essen-Mitte has several departments that took part in Clinical trials: "Kliniken Essen-Mitte, Evang. Huyssens-Stiftung, Klinik für Internistische Onkologie / Haematologie" - 6 trials, "Prof. Dr. Harald Groeben" - 3 trials, "Kliniken Essen-Mitte Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gynäkologische Onkologie" - 2 trials, "Department of Psychiatry, Psychotherapy and Addiciton Medicine, Evang. Kliniken Essen-Mitte" - 2 trials, "Ev. Krankenhaus Essen-Werden gGmbH, Zentrum für Innere Medizin, Klinik für Hämatologie, Onkologie und Stammzelltransplantation" - 2 trials